# Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Source: https://onco.cc/trials/nct05640791/  
OnCo record `nct05640791` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.

## Summary

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer is a phase 2 interventional study registered as NCT05640791 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 40 participants, started 2023-01-12 and due to reach its primary completion in 2023-12-31. Interventions recorded: Cisplatin, Gemcitabine, Nab-paclitaxel, Durvalumab. Conditions listed: Resectable Biliary Tract Cancer. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT05640791
- Phase: 2
- Setting: Phase II, Single-arm, Exploratory Study to Evaluate the Safety and Effectiveness of Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05640791: https://clinicaltrials.gov/study/NCT05640791

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct05640791.json